Metamizole (dipyrone), a non-opioid analgesic, was the most commonly prescribed pain reliever at Charité (59%) and in Germany (23%) while oxycodone (29%), a semi-synthetic opioid, was most commonly ordered in the USA. The average costs of pain therapy were also calculated and compared between the three regions. Prescription reports from the USA and Germany were collected and compared with the trends at Charite to identify the frequently prescribed pain relievers and their world-wide utilization trends. We analysed >500,000 discharge summaries from Charite, encompassing the years 2006 to 2015, and extracted the medications and diagnoses from each discharge summary. In this study we estimate the pain reliever prescription rates at a major German academic hospital center and compare with the nationwide trends from Germany and prescription reports from the USA. Pain-relief prescriptions have led to an alarming increase in drug-related abuse. Isolated and non-isolated dipyrone exposures varied with respect to patient age, exposure reason, management site, medical outcome. The most frequently reported treatment for isolated exposures was some form of decontamination (n = 11). The specific adverse clinical effects reported for isolated exposures were primarily neurological (n = 6), gastrointestinal (n = 4), and dermal (n = 3). Of those cases with a known medical outcome, the medical outcome was no adverse clinical effect for 76% (16/21) of isolated exposures and 42% (8/19) of non-isolated exposures. Twenty-two percent (11/51) of isolated cases were intentional while 59% (17/29) of non-isolated cases were intentional. Although the majority of both types of dipyrone exposures were adults (47/78 or 60%), children, less than 6 years of age, accounted for a higher proportion of isolated exposures (33% vs 10%) while a higher proportion of non-isolated exposures involved older children (28% vs 8%). Most of the dipyrone exposures occurred at the patient's own residence (72/76 or 95%) and the patients were more likely to be female (54/81 or 67%). Of 81 dipyrone exposures, 52 (64%) were isolated and 29 (36%) were non-isolated. When compared to the Census, dipyrone exposures were significantly more likely to have been reported from regions closer to the Mexican border (53% vs 9%). Isolated and non-isolated cases were compared with respect to various factors. Human dipyrone exposures reported to 6 Texas poison centers from 1998 to 2004 were identified. The purpose of this study was to describe the pattern of dipyrone exposures reported to poison centers. Many San Diego health care providers are unaware of this medication and may, therefore, miss opportunities to educate patients about safer alternatives.ĭipyrone is an analgesic and antipyretic agent. Neo-melubrina has been used by a substantial percentage of Hispanic patients in the community clinics surveyed. Providers who trained within 75 miles of the US-Mexico border, who reported a patient population of more than 50% Hispanic, and who were resident physicians at the time of the survey were most likely to answer correctly. Physicians answered correctly more often than nurse practitioners and pediatric providers more often than family medicine providers.

Most providers were unable to correctly identify why Neo-melubrina might be used or its adverse effects. Most (56%) used it for both pain and fever. Of the 200 patients, 76 (38.0%) reported a lifetime use of Neo-melubrina. Self-reported use of Neo-melubrina by patients, and provider awareness of Neo-melubrina and its most significant side effects. Providers: members of San Diego chapters of the American Academy of Pediatrics, the American Academy of Family Physicians, and the California Coalition of Nurse Practitioners. Patients: 200 parents of Hispanic pediatric patients. To define the use of Neo-melubrina in the Hispanic population of 2 San Diego, California, community clinics and to determine local physicians' and nurse practitioners' awareness of the drug and its risks. It is banned in the United States but is available in Mexico under the name Neo-melubrina. Dipyrone is an antipyretic drug that has been associated with agranulocytosis.

Neo melubrina